OTP 10: Take-Home Privileges for Unsupervised Use of Medication
|
|
The organization establishes
criteria to determine when take-home privileges can become part of an individual’s
service plan and how
medications are provided in accordance with applicable federal regulations concerning the prescription and distribution of controlled substances.
Direct
service personnel, medical and other appropriate personnel,
service recipients, and, whenever possible,
family members, participate in determining if the individual meets criteria for take-home medication.
To support the initiation of take-home privileges, the medical director considers:
- length of time in treatment;
- consistency of clinic attendance;
- clinical status;
- progress in rehabilitation;
- medical necessity;
- behavioral factors;
- geographic considerations;
- employment schedules that create hardship for an individual to meet limited clinic hours;
- results of toxicology tests; and
- other special needs.
Interpretation: “Other special needs" may include, and are not limited to, emergency circumstances, split dosing, and pain treatment.
Interpretation: All elements should be considered collectively in determining whether take home privileges are appropriate for an individual. Decisions should not be based solely on toxicology test reports.
For each person provided with take-home medication, the organization:
- schedules toxicology tests to ensure he or she consumes the opioid treatment medication provided and remains free of substance use;
- implements measures to help avoid diversion of controlled substances;
- has a physician review his or her status at least every 90 days, or more frequently if clinically indicated; and
- periodically reviews the benefits and drawbacks of continued take-home privileges.
The medical director uses established criteria to decide when take-home medication is contraindicated, including:
- signs or symptoms of withdrawal;
- evidence of continued alcohol and drug use;
- the absence of laboratory evidence of the opioid treatment medication in toxicology samples;
- potential complications from concurrent disorders;
- ongoing criminal behavior; and
- absence of stable social relationships or a stable home environment.
Individuals receive guidance on how to safely secure take-home medication.
Interpretation: The medical director considers whether the medication can be safely stored in the person’s place of residence when determining if the individual may be permitted unsupervised use of medication.
Take-home medication is prohibited for individuals receiving short-term
detoxification or interim maintenance treatment.
NA The organization does not provide short-term detoxification or interim maintenance treatment.
The organization labels take-home medication with the organization’s name, address, and telephone number.